This site is intended for health professionals only

Published on 20 November 2008

Share this story:
Twitter
LinkedIn

Debiopharm and Aurigene sign licensing agreement

teaser

Debiopharm Group – a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology – and Aurigene Discovery Technologies Ltd – a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug candidates – signed an exclusive worldwide license agreement, to develop and commercialise Debio 0617, a novel inhibitor of an undisclosed oncology pathway.

Utilising its know-how and fragment-based drug delivery technology platform, Aurigene has generated potent leads against the target.

Under the terms of the agreement, Debiopharm will pay Aurigene an upfront fee, as well as further payments according to predefined discovery, development and sales milestones.

“We are very excited to continue our collaboration with Aurigene. Their business model offers a one-stop solution for structure guided drug design, lead optimisation and preclinical work,” said Rolland-Yves Mauvernay, President & Founder of Debiopharm Group.

“The Debio 0617 project aims at developing inhibitors targeting a key oncology pathway, which plays essential roles in various solid tumors and haematological malignancies.”

C S N Murthy, CEO of Aurigene, added: “Partnering with Debiopharm, a highly focused and successful drug development company, is highly synergistic for Aurigene, a drug discovery biotech. Aurigene has been collaborating with Debiopharm on two other programmes for three years now, and the current licensing agreement with Debiopharm serves to reiterate the high quality of science and competence at Aurigene. This further strengthens the relationship between the companies.”

Debiopharm Group

 



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn